Priovant Therapeutics has initiated a Phase 2b/3 clinical trial for brepocitinib in lichen planopilaris, a rare inflammatory scalp disorder that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE